Akero Therapeutics
Compare Akero Therapeutics…Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Akero TherapeuticsEfruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.